东盟上市后信息交换指引：区域联动对柬埔寨的含义

1. Key takeaway

The Guidelines for Medical Device Post-Market Information Exchange were adopted at the 12th meeting of the ASEAN Medical Device Committee (AMDC) in September 2023 and at the 60th meeting of the ASEAN Consultative Committee for Standards and Quality (ACCSQ) in December 2023.

The guidelines accompany the PMAS requirement of AMDD Article 12 and address how post-market information is exchanged between member states. For Cambodia the significance is that information collected in Cambodia after market placement enters the ASEAN-level exchange network — and, in turn, information from other member states flows into Cambodia.

GRZAN note: the guidelines were adopted at 2 meetings (September 2023 12th AMDC; December 2023 60th ACCSQ); the 14th AMDC meeting hosted by Cambodia was held on 19 to 22 August 2025 (Siem Reap).

2. Regulatory basis

3. Expert commentary

1. Regional interconnection amplifies the consequences of a local event to the regional level. A post-market event occurring in one ASEAN member state will, in principle, become known to the other member states through the exchange network. This means how a case is handled in one country becomes a reference for the others; the cost of concealment or delay far exceeds that of proactive reporting.

1. Cambodia hosting the 14th AMDC meeting signals rising participation in regional mechanisms. From 19 to 22 August 2025, the 14th AMDC meeting was held in Siem Reap, Cambodia. Hosting a regional meeting is usually accompanied by domestic housekeeping and alignment; companies may read this as a signal that Cambodian regulation is gradually becoming more formalised.

1. Information exchange and the ”Single Submission Model” are two sides of the same trend. The 2023 information exchange guidelines address the regional circulation of post-market information; the Single Submission Model advanced in 2026 addresses the regional circulation of pre-market technical dossiers (see article 48). Taken together, ASEAN is drifting slowly from country-by-country registration towards regional coordination, but the final say remains with each country.

4. Practical recommendations

1. Maintain a single ASEAN-wide vigilance event ledger instead of recording country by country. Mark in the ledger the country where the event occurred, the countries reported to and the scope of exchange, so that enquiries from any member state can be answered.
2. Proactive reporting beats reactive response. Under the exchange network, information flows regardless of a company’s wishes. Reporting early and reporting fully generally produces a more favourable regulatory outcome.
3. Track AMDC meeting outcomes. Domestic follow-up actions usually follow after Cambodia hosts a meeting; it is advisable to add AMDC meeting minutes and DDF website announcements to routine monitoring.

5. Verification checklist

• □ An ASEAN-wide vigilance event ledger has been established
• □ The ledger records the country of the event, the countries reported to and the scope of exchange
• □ Internal processes are designed on a ”proactive reporting first” basis
• □ AMDC meeting outcomes are included in the monitoring list
• □ Cambodia’s hosting of the 14th AMDC meeting (19 to 22 August 2025, Siem Reap) has been recorded
• □ It is understood that regional interconnection does not transfer each country’s final decision-making power

Regulatory information verified as of 29 October 2026.

In Southeast Asia, GRZAN’s core capabilities focus on three areas. First, tracking the legislative progress of dedicated medical device laws across member states — Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established written device regulatory frameworks, whereas Cambodia still has no dedicated Medical Device Law. The current rules are assembled from three layers: the legal basis for registration numbers provided by the 1996 Law on the Management of Pharmaceuticals and its 2007 amendment, the classification and procedures provided by Prakas No. 1258 of 2012, and the technical framework of the ASEAN Medical Device Directive. Regulatory certainty is therefore markedly lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN may act as the manufacturer’s statutory representative in Cambodia, carrying registration submissions, regulatory communication and post-market reporting obligations, and assisting with the practical implementation of the Cambodian registered pharmacist and pharmaceutical import/export enterprise licence requirements. Third, quality system and testing support: assisting with the establishment of a quality management system meeting ISO 13485 requirements, and organising the technical dossier in accordance with the ASEAN Common Submission Dossier Template (CSDT).

Business enquiries: info@grzanglobal.com